Scientia Advisors in the News

---

Publications

---

Press Releases

---

Events

---

Luminary Insights

---

Media Contact

---

Conferences

Scientia Advisors to Participate in Expert Reimbursement Panel and in Regulation of Molecular Diagnostic Testing at Molecular Med Tri-Con 2011

Session 1

Molecular Diagnostics Program
Expert Reimbursement Panel: Changing Landscape of Valuation and Reimbursement

Patrick Terry will participate in this panel which will address the following topics:

• Enable more transparency, which in turn should promote more rational coverage decisions
• Study design: RCT vs observational vs. retrospective data what evidence is needed for decision making?
• How can technology companies bridge the gap to reimbursement?
• Does working with pharma help to get diagnostics to the market and paid for?
• Regulatory environment: how does it affect reimbursement decisions (CMS, FDA) vs LDT?
• Tools for access (e.g. prior authorization): A new way for value
• Coding system
• Will new, costly therapies (e.g. biologics) save the day for Dx?

Panelists

• Felix W Frueh, Ph.D., President, Medco Research Institute, Medco Health Solutions, Inc. - Moderator
• Leah Sparks, Vice President, Business Development, DNA Direct
• Patrick Terry, Principal, Pricing and Market Access Practice, Scientia Advisors LLC
• Kristin Ciriello Pothier, Partner, Health Advances, LLC

Session 2

Joint Session of the Molecular Diagnostics and Personalized Diagnostics Conferences
Regulation of Molecular Diagnostic Testing: Three Points of View

Harry Glorikian will chair this keynote session which will include the following presentations:

• Regulation of Molecular Diagnostics by Alberto GutierrezAlberto Gutierrez, Ph.D., Deputy Director, Office of in vitro Diagnostic Device Evaluation and Safety, Food & Drug Administration
• Genomic Medicine: The Pathway from Biobanks to Clinical Practice by Timothy O'LearyTimothy J. O'Leary, M.D., Ph.D., President-Elect, Association for Molecular Pathology; Deputy Chief Officer, R&D Office; Director, Biomedical Laboratory and Clinical Science R&D Service, Veterans Health Administration
• Is the Past Prologue - Will Proposed Changes Really Result in Dramatic Changes in the Regulation of Testing? by Stephen DayStephen P. Day, Ph.D., Director, Medical Affairs, Hologic, Inc.

More information at Molecular Med Tri-Conference website.